Spyre Unveils SPY003 20-Week Data Supporting Quarterly or Biannual Dosing
Spyre presented 20-week Phase 1 data for SPY003 showing a differentiated pharmacokinetic profile that supports quarterly or biannual dosing and demonstrated targeted biological activity through reduced downstream cytokines. Preclinical mouse colitis studies revealed that combined anti-TL1A and anti-IL-23 therapy delivers superior efficacy versus individual agents, underscoring its SKYLINE platform approach.
1. Phase 1 SPY003 Interim Results
Spyre shared follow-up data through 20 weeks showing SPY003 was well tolerated, exhibited an extended half-life supporting quarterly and semiannual maintenance dosing, and achieved targeted biological activity via significant reductions in downstream cytokines.
2. SKYLINE UC Platform Study
The company detailed its SKYLINE-UC trial evaluating three long-acting antibodies as monotherapies and in combination to assess efficacy and safety, aiming to identify optimal dosing regimens for ulcerative colitis.
3. Preclinical Combination Efficacy
In a mouse anti-CD40 colitis model, dual targeting of TL1A and IL-23 outperformed each monotherapy, indicating that the combination approach may offer superior efficacy in inflammatory bowel disease management.